Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

Ptc,Therapeutics,Sign,,Logo,At,Pharmaceutical,Company,Office,-,Sunnyvale,

On Saturday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released new Phase 3 PEGASUS study results on Saturday.

The data show that its therapy Palynziq (pegvaliase-pqpz) significantly reduced blood phenylalanine (Phe) levels in adolescents with phenylketonuria (PKU), a rare metabolic disorder.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.